This Week in Pulmonary — May 28, 2026

Welcome to This Week in Pulmonary. This week we're covering 10 notable papers spanning the spectrum of COPD management, new directions in lung cancer therapy, and a look at diagnostics, policy, and foundational science impacting our field. Let's dive in.

COPD Management and Outcomes

We begin with a focus on COPD, a disease where comorbidities and exacerbations drive much of the morbidity and mortality. Two large cohort studies this week underscore this reality. First, a study in Respiratory Medicine using data from the UK Biobank looked at the combined impact of COPD and cardiovascular disease [5]. Among nearly 300,000 participants followed for a median of 13 years, those with both conditions at baseline had more than double the risk of all-cause mortality compared to those with neither. While the interaction wasn't strictly multiplicative, the absolute burden was profound. At 10 years, the excess risk for patients with both diseases was nearly 14 percentage points. To put that in clinical terms, for every seven patients with coexisting COPD and cardiovascular disease, one additional death occurred that would not have happened if they only had one or neither of the conditions. This highlights a distinct, high-risk patient group needing integrated cardiopulmonary management.

Building on this, another study in Respiratory Medicine, this one from Israel, quantified the long-term risk following a single acute exacerbation of COPD [6]. In a matched cohort of over 51,000 newly diagnosed COPD patients, experiencing a first moderate or severe exacerbation was associated with a 19% increased risk of a future composite cardiopulmonary event. The risk was particularly high for subsequent severe respiratory events, including a 51% increased risk for another severe exacerbation, a 58% increased risk for needing mechanical ventilation, and an 82% increased risk for acute respiratory failure. These findings reinforce the idea that an exacerbation is not just a transient event but a sentinel marker for long-term decline, demanding close and proactive follow-up.

Given these risks, new therapeutic strategies are always needed. ERJ Open Research published a phase 2a trial of a novel anti-inflammatory macrolide, EP395 [2]. The goal is to capture the immunomodulatory benefits of drugs like azithromycin without the risk of inducing antimicrobial resistance. In this 12-week, double-blind trial involving 61 stable COPD patients, the drug was well tolerated. While this was primarily a safety study, it did show pharmacodynamic effects, significantly reducing sputum neutrophil elastase, a key inflammatory mediator. Importantly, exploratory analysis of the lung microbiome showed no detectable effect, suggesting it may avoid the resistance concerns of traditional macrolide antibiotics. This is an early but promising step toward a new class of non-antibiotic, anti-inflammatory therapy for COPD.

Finally in our COPD section, a paper in the American Journal of Respiratory and Critical Care Medicine provides new insights into phenotyping using data from the ECLIPSE study [10]. It explored the functional consequences of airway mucus plugs using respiratory oscillometry. The analysis found that in over 1,200 patients, the 38% who had mucus plugs on CT scans also had distinct oscillometry findings, specifically higher peripheral airway resistance and reactance. This association held even after adjusting for FEV1 and emphysema severity. This suggests that respiratory oscillometry could serve as a non-invasive functional biomarker to identify patients impacted by mucus plugging, potentially guiding targeted therapies like mucolytics.

Advances in Non-Small Cell Lung Cancer

Turning to lung cancer, we have two papers that address tailoring therapy, one based on patient frailty and the other on specific tumor genetics. First, in PLoS Medicine, a Chinese randomized trial tackled a common clinical dilemma: how to treat older or frail patients with stage III non-small-cell lung cancer who are ineligible for standard concurrent chemoradiotherapy [7]. Patients were randomized to sequential chemo-immunotherapy followed by either standard-dose or reduced-dose thoracic radiotherapy.

Results This was a small, non-comparative cohort trial, so we must interpret the results with caution. The 1-year progression-free survival was 84.3% in the standard radiotherapy group versus 70.7% in the reduced radiotherapy group. As expected, severe adverse events were less common with the lower radiation dose, with 54% experiencing grade 3 or 4 events compared to 71% in the standard-dose arm.

Conclusions The authors conclude that for this vulnerable population, a reduced-dose radiation strategy might be feasible and offer a better safety profile with numerically similar, though slightly lower, survival outcomes. However, they stress that these are exploratory findings that require confirmation in larger trials designed to test for non-inferiority.

Next, a highly practical paper from the Journal of Thoracic Oncology provides new clarity on managing compound EGFR mutations [8]. While we often think of EGFR mutations as single events, they can occur in combination. This study analyzed over 15,000 EGFR-mutant samples and focused on a subgroup called P-loop and alpha-C helix compressing, or PACC mutations. The key finding was that PACC mutations were found in 9% of samples and, unlike classical mutations, they predominantly occurred as compound mutations. In vitro models and retrospective clinical data from over 1,500 patients revealed a crucial pattern: NSCLC harboring either single or compound PACC mutations had better outcomes with second-generation TKIs, like afatinib, compared to first- or third-generation TKIs. This is a significant finding that directly challenges the common reflex to use third-generation inhibitors like osimertinib for complex mutations and suggests a more tailored approach is needed for patients with PACC-type mutations.

Diagnostics, Policy, and Foundational Science

Our final section covers a diverse set of topics, from advanced imaging to basic science and health policy. First, in ERJ Open Research, a study validates a promising automated CT biomarker for fibrotic interstitial lung diseases beyond just IPF [3]. The e-Lung weighted reticulovascular score, or WRVS, was evaluated in over 600 patients with non-IPF ILD. A higher baseline score was strongly associated with mortality. A baseline WRVS of 15% or greater was associated with a 3- to 4-fold increased risk of death. Even more clinically relevant for follow-up, a serial increase in the score of just 3% on a subsequent CT scan was also linked to a significantly increased risk of mortality. This provides a quantitative, objective tool for risk stratification and monitoring disease progression in a broad range of fibrotic ILDs.

Next, a fascinating basic science paper in Nature introduces the concept of inflammatory memory in our own blood-forming stem cells [4]. Using xenograft models and single-cell analysis, researchers identified a subset of human hematopoietic stem cells that retain a molecular memory of previous inflammatory stress. These cells, termed HSC-iM, become more quiescent and less productive. This molecular signature was then found in human samples from diverse conditions like aging, sickle cell disease, and post-COVID-19 recovery. Strikingly, enrichment of this inflammatory memory program in circulating blood cells was associated with a higher risk score for all-cause mortality in large population cohorts. This provides a potential mechanism explaining how past inflammatory events can have long-lasting consequences on health and longevity.

Finally, we look at two policy-focused position papers. First, in the American Journal of Respiratory and Critical Care Medicine, the American Thoracic Society reviews the United States Air Quality Index, or AQI [1]. The committee's conclusion is stark: despite its widespread use, there is a significant lack of evidence on whether the AQI actually changes behavior or improves health outcomes, particularly for individuals with respiratory disease. The paper calls for a new research agenda to evaluate how patients interpret AQI messages, whether they change their behavior, and if those changes lead to meaningful reductions in exposure and better health. It's a call to strengthen the scientific foundation of our primary public health tool for air pollution.

And second, in the Annals of Internal Medicine, the American College of Physicians weighs in on the growing role of private equity and corporatization in healthcare [9]. The position paper notes that private equity investment is often associated with increased costs and, in some settings, negative effects on care quality. It highlights the challenges to physician autonomy and the need for more vigorous enforcement of regulations. The ACP calls for policy solutions that strengthen oversight, transparency, and accountability to ensure that patient care and the physician workforce are protected as corporate investment in medicine continues to grow.

Editor's Pick

If you only have time for one paper this week, make it the study on EGFR PACC mutations in the Journal of Thoracic Oncology [8]. This work provides immediately actionable clinical guidance, suggesting that a specific subset of EGFR-mutant lung cancer patients may derive more benefit from second-generation TKIs than third-generation agents, a counterintuitive finding that could change practice for this group.

Clinical Bottom Line

Here are the key takeaways from this week in Pulmonary.

First, the combination of COPD and cardiovascular disease defines a major high-risk group. The absolute 10-year mortality risk is so high that for every 7 patients with both conditions, one excess death occurs.

Second, in non-IPF fibrotic lung disease, an automated CT score called WRVS can help risk-stratify patients. A baseline score over 15% or a serial increase of just 3% are powerful predictors of mortality.

Third, for frail patients with stage III lung cancer unable to receive concurrent chemoradiotherapy, sequential chemo-immunotherapy with reduced-dose radiation appears to be a feasible strategy with a better safety profile, though larger trials are needed.

Fourth, a moderate or severe COPD exacerbation is a major warning sign, significantly increasing the long-term risk of severe respiratory complications and the need for mechanical ventilation.

And finally, when treating EGFR-mutant lung cancer, identify PACC mutations. These often occur in combination with other mutations and appear to respond better to second-generation TKIs than third-generation agents.

That's your roundup for This Week in Pulmonary. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.